Perpetua Medical AB (publ) OMXSTO:PERP_B:
SUBSIDIARY SPIROTRONIC RECEIVES SIGNIFICANT ORDER FROM LEADING MEDTECH COMPANY
ORDER COULD GENERATE 6 MILLION SEK CONSULTING REVENUES IN 2026
Perpetua Medical's Subsidiary Gets Significant Order
Earlier from Perpetua Medical
- PERP_B: Q2 2025 sales up 165%, losses reduced, major acquisition and asset sale boost outlook
- PERP_B: Strong sales growth from ES-Medical offset by negative operating result and strategic realignment
- PERP_B: Q4 revenue jumped 62% on ES-Medical, with improved losses and strong cash flow
- PERP_B: First acquisition completed, losses reduced, and cost base lowered as strategic shift advances
- PERP_B: Operating loss narrowed, cash position strengthened, and acquisition strategy advanced
Later from Perpetua Medical
- Perpetua Medical Q3 Net Sales At SEK 3.48 Mln
- Perpetua Medical Approves Directed New Issue Of Up To 2,355,713 Shares
- Perpetua Medical Q4 Oper Loss Widens To SEK 3.9 Mln
- PERP_B: Revenue up 54% year-over-year, but operating loss widened; strong cash supports acquisition focus
Follow Perpetua Medical into a list and get an email when it puts out news.
Follow Perpetua Medical